FAST NEWS: Connect Biopharma Plunges Despite Positive Drug Trial Results
The latest: Connect Biopharma (CNTB.US) said on Tuesday its CBP-201 drug candidate achieved all primary and key secondary endpoints in the primary analysis population for a 16-week pivotal trial of…
FAST NEWS: Connect Biopharma Plunges on Poor Results for Colitis Drug
The latest: Connect Biopharma (CNTB.US) said late on Tuesday that results from a Phase 2 trial for its CBP-307 drug for treatment of patients with moderate to severe ulcerative colitis…
Connect Biopharma’s Latest Dermatitis Drug Update Fails to Pump Up Shares
Company’s stock sank after it released data on Phase 2b trials for its atopic dermatitis drug, a potential competitor to Regeneron-Sanofi blockbuster Dupixent Key takeaways: Loss-making Connect Biopharma says Phase…
RELATED ARTICLES
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK -
Everest reaches new heights on growing drug sales
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
FAST NEWS: Simcere’s Covid drug trial shows promising results
2096.HK
